Cargando...

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab

In selected patients with moderate to severe active ulcerative colitis who have failed to respond or are poorly responsive to standard pharmacologic forms of treatment with corticosteroids and immunosuppressive agents, therapy with a biological agent may be considered. While infliximab is an establi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Autor Principal: Freeman, Hugh J
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2013
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3826758/
https://ncbi.nlm.nih.gov/pubmed/24235838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S38852
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!